Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the first nine months of 2025 [1]. Industry Summary - In September 2025, the production of chemical pharmaceutical raw materials in China was 295,000 tons, representing a year-on-year decrease of 3.6% [1]. - Cumulatively, from January to September 2025, the total production of chemical pharmaceutical raw materials reached 2.721 million tons, showing a cumulative growth of 1.2% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the chemical pharmaceutical sector include Heng Rui Medicine (600276), East China Pharmaceutical (000963), Lizhu Group (000513), Baiyunshan (600332), North China Pharmaceutical (600812), Haizheng Pharmaceutical (600267), Fosun Pharmaceutical (600196), Kelun Pharmaceutical (002422), Enhua Pharmaceutical (002262), and Xianju Pharmaceutical (002332) [1].

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has announced a delay in the "High-end Formulation Internationalization Construction Project" to December 31, 2026, due to pending product approvals and to mitigate fundraising risks [1][2]. Group 1: Project Update - The company raised 1 billion yuan through a private placement in 2020, with a net amount of 987 million yuan allocated for the project, which originally aimed for completion by December 31, 2025 [1]. - As of October 31, 2025, 636 million yuan has been invested in the project, achieving a progress rate of 90.79%, with major construction completed and production line installation nearly finished [1]. - Remaining funds will be used for construction, cleanroom facilities, and necessary testing equipment for the formal production phase [1]. Group 2: Financial Performance - The company's revenue for 2023 and 2024 is projected to be 4.123 billion yuan and 4.001 billion yuan, reflecting year-on-year declines of 5.85% and 2.98% respectively [3]. - Net profit for the same years is expected to be 563 million yuan and 397 million yuan, with significant year-on-year decreases of 24.86% and 29.46% [3]. - For the first three quarters of 2025, revenue was 2.826 billion yuan, down 12.71%, and net profit was 407 million yuan, down 23.29% [4]. Group 3: Regulatory Issues - In 2025, the company faced regulatory penalties for alleged price monopoly in raw materials and issues related to fundraising management [5][6]. - The Tianjin Market Supervision Administration imposed a fine totaling 195 million yuan for violating antitrust laws related to the pricing of dexamethasone phosphate sodium [6]. - The Zhejiang Securities Regulatory Commission issued warning letters to the company and its executives for fundraising management issues [6].

Core Viewpoint - Xianju Pharmaceutical announced a one-year extension for its fundraising project "High-end Formulation Internationalization Construction Project" while maintaining the project’s implementation subject, location, funding purpose, and investment scale unchanged [1][2] Group 1: Project Details - The total committed investment amount for the "High-end Formulation Internationalization Construction Project" is 700 million yuan, with 636 million yuan already invested as of October 31, 2025, representing a progress of 90.79% [1] - The remaining funds will be used for civil construction, cleanroom facilities, equipment warranty payments, and supporting testing facilities required for the formal production phase of certain products [1] - The project’s main buildings have completed construction and received acceptance reports for environmental protection, fire safety, and safety inspections [1] Group 2: Reasons for Delay - The project’s timeline has been extended from December 31, 2025, to December 31, 2026, due to pending approvals for some declared products and the production lines not yet being officially operational [2] - The company aims to strategically position itself for capacity expansion in high-end formulation international products, which involves establishing a new formulation technology platform [2] - The nature of pharmaceutical research, characterized by long cycles, multiple stages, and high technical difficulty, contributes to the uncertainty in the approval timeline for product formulations [2] Group 3: Financial Performance - Xianju Pharmaceutical has faced declining performance, with revenue and net profit both decreasing for two consecutive years in 2023 and 2024 [3] - For the first three quarters of this year, the company reported revenue of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to shareholders of 407 million yuan, down 23.29% year-on-year [3] Group 4: Regulatory Issues - In September, the company and its chairman received warning letters due to violations related to the misuse of raised funds, including not following proper review procedures and using raised funds for unrelated expenses [4] - The Zhejiang Securities Regulatory Bureau held the chairman and other executives responsible for these violations and decided to implement supervisory measures, including warning letters [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 √ 是 □ 否 √ 是 □ 否 如否，请详细说明：______________________________ 十五、被提名人具备上市公司运作相关的基本知识，熟悉相关法律、行政法规、部门规章、规范性文件 及深圳证券交易所业务规则，具有五年以上法律、经济、管理、会计、财务或者其他履行独立董事职责 所必需的工作经验。 √ 是 □ 否 如否，请详细说明：______________________________ 十六、以会计专业人士被提名的，被提名人至少具备注册会计师资格，或具有会计、审计或者财务管理 专业的高级职称、副教授或以上职称、博士学位，或具有经济管理方面高级职称且在会计、审计或者财 务管理等专业岗位有五年以上全职工作经验。 □ 是 □ 否 √ 不适用 如否，请详细说明：______________________________ 十七、被提名人及其直系亲属、主要社会关系均不在公司及其附属企业任职。 如否，请详细说明：______________________________ 十四、被提名人担任独立董事不会违反其他法律、行政法规、部门规章、规范性文件和深 ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. announced an organizational restructuring aimed at improving governance and operational efficiency by eliminating the supervisory board and optimizing management layers [1][2]. Group 1: Organizational Restructuring - The company held its 18th meeting of the 8th Board of Directors on November 27, 2023, where the proposal for organizational restructuring was approved [1]. - The restructuring is in response to the latest revisions of the Company Law, Securities Law, and the company's articles of association, focusing on streamlining governance levels and clarifying departmental responsibilities [1][2]. - The new governance structure will consist of a three-tier system: the Shareholders' Meeting as the highest authority, the Board of Directors, and the Management Team overseeing various functional departments and business units [1][2]. Group 2: New Organizational Structure - The adjusted organizational structure includes the Shareholders' Meeting, Board of Directors, four specialized committees (Audit Committee, Compensation and Assessment Committee, Nomination Committee, and Strategy and Sustainable Development Committee), and a Board Secretary [2]. - Management will oversee functional departments such as Corporate Management and Development, Production Management, Procurement, Finance, Human Resources, Audit, Administrative Affairs, Information, and the Board Secretary's Office, along with business departments and special units [2]. - The company asserts that this restructuring aligns with regulatory requirements and its developmental needs, with the Board committing to accurate and complete information disclosure [2].

截至发稿，仙琚制药市值为93亿元。 每经头条（nbdtoutiao）——灌水21万亿，高市早苗1.7万亿强化国防！日本负债率已远超债务危机时的 希腊，对美巨额投资致大规模资本外流，"卖出日元成国际趋势" 每经AI快讯，仙琚制药（SZ 002332，收盘价：9.39元）11月27日晚间发布公告称，公司第八届第十八 次董事会会议于2025年11月27日在公司会议室召开。会议审议了《关于公司董事会换届选举独立董事的 议案》等文件。 2025年1至6月份，仙琚制药的营业收入构成为：医药占比99.34%，其他业务占比0.66%。 （记者 曾健辉） ...

中信建投证券股份有限公司 关于浙江仙琚制药股份有限公司 部分募集资金投资项目延期的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为浙江仙琚制药股份有限公司（以下简称"仙琚制药"、"公司"）2020年度 非公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第13号——保 荐业务》和《上市公司募集资金监管规则》等有关规定，对仙琚制药部分募集资 金投资项目延期的情况进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准浙江仙 琚制药股份有限公司非公开发行股票的批复》（证监许可〔2020〕2217 号）核准， 浙江仙琚制药股份有限公司（以下简称"公司"）非公开发行人民币普通股股票 （A 股）72,992,700 股，每股面值 1 元，发行价格为 13.70 元/股，募集资金总额 为人民币 999,999,990 元，扣除相关发行费用后，实际募集资金净额为人民币 987,357,806.75 元。天健会计师事务所（特殊普通合伙）已对本次募集资金的实收 情 ...

浙江仙琚制药股份有限公司 内部审计制度 浙江仙琚制药股份有限公司 内部审计制度 第一章 总则 第一条 为了加强浙江仙琚制药股份有限公司(以下简称"公司")的内部审计工作，提高内部审计工作 质量，保护投资者合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《中华人民共和 国审计法》《审计署关于内部审计工作的规定》《深圳证券交易所股票上市规则》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作指引》等法律、法规、规范性文件和《浙江仙琚制 药股份有限公司章程》的规定，结合公司实际情况，制定本制度。 第二条 本制度所称内部审计，是指公司内部审计机构或人员，对其内部控制和风险管理的有效性、财 务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活动。公司依法实行内部审计制 度，以加强内部管理和监督，遵守国家法规，维护公司合法权益，促进改善经营管理，提高经济效益。 第三条 本制度所称内部控制，是指公司董事会、高级管理人员及其他有关人员为实现下列目标而提供 合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （四）确保公司信息披露的真实、准确、完整和公平。 第四条 ...

浙江仙琚制药股份有限公司 董事会薪酬与考核委员会工作条例 第一章 总则 第一条 为进一步建立健全浙江仙琚制药股份有限公司（以下简称"公司"）董 事(非独立董事)及高级管理人员的考核和薪酬管理制度，完善薪酬体系，根据《中 华人民共和国公司法》《上市公司治理准则》《公司章程》等规定，制定本工作 条例。 浙江仙琚制药股份有限公司董事会 薪酬与考核委员会工作条例 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制定公司董 事及高级管理人员的考核标准并进行考核，负责制定、审查公司董事及高级管理 人员的薪酬政策与方案,向董事会提出建议。 第三条 本条例所称董事是指在本公司支取薪酬的董事长、董事，高级管理人员 是指董事会聘任的总经理、副总经理、董事会秘书、财务负责人及由总经理提请 董事会认定的其他高级管理人员。 第一章 人员组成 第四条 薪酬与考核委员会由三名董事成员组成，其中独立董事二名。 第五条 薪酬与考核委员会委员由董事长、二分之一独立董事或者全体董事的三 分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员(召集人)一名，由董事长董事会推荐独立 董事担任，负责主持委员会工作；主任委员在委 ...

重大信息内部报告制度 浙江仙琚制药股份有限公司 重大信息内部报告制度 浙江仙琚制药股份有限公司 第一章 总则 第一条 为规范浙江仙琚制药股份有限公司（以下简称"本公司"或"公司"） 重大信息内部报告工作，保证公司内部重大信息的快速传递、归集和有效管理， 及时、准确、全面、完整地披露信息，维护投资者的合法权益，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号— —主板上市公司规范运作》等有关法律法规、规范性文件和公司《章程》等有关 规定，结合公司实际，制定本制度。 第二条 公司重大信息内部报告制度是指当出现、发生或即将发生可能对公司股 票及其衍生品种交易价格产生较大影响的情形或事件时，按照本制度规定负有报 告义务的公司内部信息报告义务人或联络人，应及时将相关信息通过董事会秘书 向董事会报告的制度。公司董事会秘书应对上报的重大信息进行分析和判断，如 按有关法律、法规、规范性文件及上市规则的规定需要履行信息披露义务的，应 及时向董事长报告，并提请公司董事会履行相应程序并对外披露。 第三条 本制度所称"内部信息 ...